Drugs / BRIVESTOBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05978401 | Aug 2023 → Apr 2025 | non-small cell lung carcinoma | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05909436 | Oct 2022 → Dec 2026 expected | cancer | Guangzhou Gloria Biosciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRIVESTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068215 ↗ |
| Known as | GLS-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05978401 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068215 ↗ |
| Route | Intravenous | “All subjects will receive GLS-012 intravenously Q3W.” NCT05909436 ↗ |